DALLAS, Nov. 5, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Advanced Life Sciences Holdings Inc. (OTCBB:ADLS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Advanced Life Sciences Holdings Inc. (OTCBB:ADLS) should be of particular interest to comparable companies: Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline Plc (NYSE:GSK) and Life Technologies Corp. (Nasdaq:LIFE).
It is available at: http://www.investorsoup.com/lp/ADLS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Advanced Life Sciences Holdings Inc. (ADLS) is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and respiratory disease. The Company has assembled a pipeline of clinical and preclinical product candidates. In September 2008, the Company entered into a development and commercialization agreement with Wyeth for cethromycin in the Asia Pacific region excluding Japan. Cethromycin has also completed phase III clinical trials for the treatment of respiratory tract infections.
Message Board Search for ADLS: http://www.boardcentral.com/boards/ADLS
In the report, the analyst notes:
"Since ADLS' inception, it has incurred net losses each year. Its net loss for the six months ended June 30, 2009, was $4.9 million. As of June 30, 2009, ADLS had an accumulated deficit of $127.2 million. The Company has funded operations to date primarily from debt financings and capital contributions from its founder and CEO, proceeds from the initial public offering of the Company's common stock, the subsequent sale of its common stock in three private placements, including its commercial partnership agreement with Wyeth, and borrowings under the Company's bank line of credit.
"ADLS last month announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague."
To read the entire report visit: http://www.investorsoup.com/lp/ADLS
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.